Aardvark Therapeutics, Inc. (AARD) stock
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.33−0.19 (-12.50%)
Close on Nov 13, 2026Market cap $29.11MP/E –Yield –
Aardvark Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aardvark Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $56.99M, up 33.5% year over year. For fiscal 2025 it was $48.94M, up 181.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.94M | +181.8% |
| FY2024 | Dec 31, 2024 | $17.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.67M | +14.1% |
| Q2 FY2026 | Jun 30, 2026 | $10.46M | -20.5% |
| Q1 FY2026 | Mar 31, 2026 | $16.57M | +113.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.30M | +77.4% |
| Q3 FY2025 | Sep 30, 2025 | $13.74M | +237.9% |
| Q2 FY2025 | Jun 30, 2025 | $13.15M | +226.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.76M | +542.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.06M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.07M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.03M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.21M | – |
See a number that looks wrong?